Clinical data | |
---|---|
Routes of administration | Oral |
ATC code | |
Pharmacokinetic data | |
Bioavailability | 80–90% |
Protein binding | 5–7% |
Metabolism | Hepatic deacetylation Minor involvement of CYP2D6 and CYP2A6 |
Elimination half-life | 5–7 hours |
Excretion | Renal |
Identifiers | |
IUPAC name
| |
CAS Number |
|
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII |
|
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C19H28N2O4 |
Molar mass | 348.443 g·mol |
3D model (JSmol) | |
SMILES
| |
InChI
| |
(what is this?) (verify) |
Roxatidine acetate is a specific and competitive histamine H2 receptor antagonist drug that is used to treat gastric ulcers, Zollinger–Ellison syndrome, erosive esophagitis, gastro-oesophageal reflux disease, and gastritis.
Pharmacodynamic studies showed that 150 mg of roxatidine acetate were optimal in suppressing gastric acid secretion, and that a single bedtime dose of 150 mg was more effective than a dose of 75 mg twice daily in terms of inhibiting nocturnal acid secretion.
It was patented in 1979 and approved for medical use in 1986. It is available in countries including China, Japan, Korea, Germany, Italy, the Netherlands, Greece and South Africa.
Synthesis
The reductive amination between piperidine (1) and 3-hydroxybenzaldehyde (2) gives 3-(1-Piperidinylmethyl)phenol (3). William ether synthesis with N-(3-Bromopropyl)phthalimide (4) gives PC12898565 (5). W.K. deprotection with hydrazine yielded (3-(1-piperidinylmethyl)phenoxy)propylamine (6). Heating with glycolic acid (7) gave the amide (8). Acetylation with acetic anhydride completed the synthesis of (9).
References
- ^ Murdoch D, McTavish D (August 1991). "Roxatidine acetate. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic potential in peptic ulcer disease and related disorders". Drugs. 42 (2): 240–260. doi:10.2165/00003495-199142020-00006. PMID 1717223. S2CID 46973503.
- ^ BioSpectrum Bureau 1 November 2012 Sinhuan's generic heart drug gets production approval
- Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 444. ISBN 9783527607495.
- Castaer, J.; Serradell, MN; TZU-0460. Drugs Fut 1985, 10, 12, 995.
- Kenyu Shibata, 7 More », EP0024510 (1983 to Teikoku Hormone Mfg. Co., Ltd.).
- Zhang Yang, et al. WO2019075976 (to Beijing Xuansheng Pharmaceutical Co Ltd).
- Guo Rongyao & Wang Xiaofeng, CN107698538 (2018 to Inner Mongolia Jingdong Pharmaceutical Co Ltd).
- 刘占滨, et al. CN102993121 (2013 to HARBIN PHARMACEUTICAL GROUP SANJING PHARMACEUTICAL CO Ltd).
- He Minrong, CN101717363 (2012 to Jiangsu Baosheng Longcheng Pharmaceutical Co Ltd).
Drugs for peptic ulcer and GERD/GORD (A02B) | |
---|---|
H2 antagonists ("-tidine") | |
Prostaglandins (E)/ analogues ("-prost-") | |
Proton-pump inhibitors ("-prazole") | |
Potassium-competitive acid blockers ("-prazan") | |
Others | |
Combinations | |
|
This drug article relating to the gastrointestinal system is a stub. You can help Misplaced Pages by expanding it. |